LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following investor conferences in November 2021: Read more…
Brings more than 15 years of CNS drug discovery and development experience Copenhagen, Denmark and Boston, US, 1st November 2021 – Muna Therapeutics (“Muna”), pioneering the development of novel, first-in-class small molecule therapeutics for neurodegenerative diseases, today announces the appointment of Dr. Niels Plath as Chief Scientific Officer. Read more…
LONDON, 29 October 2021: Arix Bioscience plc (LSE: ARIX, “Arix”), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Aura Biosciences, Inc., (“Aura”), has announced the pricing of its initial public offering of 5,400,000 shares of common stock at a public offering price of […]
eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage biotechnology company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, will be attending the following conferences for November 2021: Read more…
Winning scientific poster shows complete tumor regression and high tolerability of SYNtecan E™ based ADCs SYNtecan E™ linker-payload is developed by Synaffix based on the potent DNA topoisomerase 1 inhibiting exatecan Additionally, Synaffix was awarded ‘Runner-Up’ for the 2021 Best ADC Platform Technology (Winner in 2020) AMSTERDAM, NETHERLANDS – 28 October 2021 — Synaffix B.V., a […]
